Trial intelligence / Profile preview

Fampridine-SR Extension in MS

NCT00649792Phase 3Completed

Sponsor
Acorda Therapeutics
Start
Aug 2007
Primary completion
Jan 2011
Modality
Small Molecules
Countries
2
01

Overview

A Phase 3 trial of dalfampridine in multiple sclerosis (MS), sponsored by Acorda Therapeutics. Started Aug 2007; status: completed.

02

Drugs

dalfampridine
03

Conditions

multiple sclerosis (MS)

Beyond the preview

Go deeper on NCT00649792.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00649792.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call